11:42 AM EDT, 05/21/2024 (MT Newswires) -- Lexaria Bioscience ( LEXX ) said Tuesday it received new patents in the US covering DehydraTech-processed cannabidiol, one as a hypertension drug and another as an epilepsy treatment.

The new patents are the third granted in the US in both patent families and will expire in 2042 if not extended, the company said.

Lexaria said it now has 43 granted patents worldwide in its portfolio.

Shares of the company rose more than 2% in recent trading.

Price: 3.00, Change: +0.08, Percent Change: +2.74